tradingkey.logo
tradingkey.logo

MiMedx Group Inc

MDXG
View Detailed Chart
4.100USD
-0.030-0.73%
Close 03/25, 16:00ETQuotes delayed by 15 min
320.17MMarket Cap
12.47P/E TTM

MiMedx Group Inc

4.100
-0.030-0.73%
Intraday
1m
30m
1h
D
W
M
D

Today

-0.73%

5 Days

-3.30%

1 Month

-22.35%

6 Months

-41.26%

Year to Date

-39.44%

1 Year

-48.10%

View Detailed Chart

TradingKey Stock Score of MiMedx Group Inc

Currency: USD Updated: 2026-03-25

Key Insights

MiMedx Group Inc's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 43 out of 391 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 9.67.In the medium term, the stock price is expected to trend down.Despite a very weak market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

MiMedx Group Inc's Score

Industry at a Glance

Industry Ranking
43 / 391
Overall Ranking
137 / 4547
Industry
Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score
Previous score

Media Coverage

Last 24 hours
Coverage Level

Very Low
Very High
Neutral

MiMedx Group Inc Highlights

StrengthsRisks
MiMedx Group, Inc. is a placental biologics company focused on providing a portfolio of products for applications in the wound care, burn, and surgical sectors of healthcare. Its product portfolio categories include Wound Care and Surgical. The Wound Care products include EPIFIX and EPIEFFECT, which are marketed for external use, such as in advanced wound care applications. Its EPICORD, EPICORD Expandable and EPIEFFECT product lines also offer an alternative treatment option to address larger, deeper wounds. Its Surgical and Other product offering includes AMNIOFIX and AMNIOEFFECT, which are used in a variety of applications and surgical settings, including lower extremity repair, plastic surgery, vascular surgery and multiple orthopedic repairs and reconstructions. It also offers HELIOGEN, an advanced bovine collagen matrix containing type I and type III collagen that is intended for the management of moderately to heavily exudating wounds and to control minor bleeding.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 30.22% year-on-year.
Fairly Valued
The company’s latest PE is 12.47, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 106.79M shares, decreasing 2.60% quarter-over-quarter.
Held by CI Select Canadian Equity Fund
Star Investor CI Select Canadian Equity Fund holds 2.01K shares of this stock.

Analyst Rating

Based on 6 analysts
Buy
Current Rating
9.667
Target Price
+127.99%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

MiMedx Group Inc News

More news coming soon, stay tuned...

Financial Indicators

EPS

Relevant data have not been disclosed by the company yet.

Total revenue

Relevant data have not been disclosed by the company yet.

MiMedx Group Inc Info

MiMedx Group, Inc. is a placental biologics company focused on providing a portfolio of products for applications in the wound care, burn, and surgical sectors of healthcare. Its product portfolio categories include Wound Care and Surgical. The Wound Care products include EPIFIX and EPIEFFECT, which are marketed for external use, such as in advanced wound care applications. Its EPICORD, EPICORD Expandable and EPIEFFECT product lines also offer an alternative treatment option to address larger, deeper wounds. Its Surgical and Other product offering includes AMNIOFIX and AMNIOEFFECT, which are used in a variety of applications and surgical settings, including lower extremity repair, plastic surgery, vascular surgery and multiple orthopedic repairs and reconstructions. It also offers HELIOGEN, an advanced bovine collagen matrix containing type I and type III collagen that is intended for the management of moderately to heavily exudating wounds and to control minor bleeding.
Ticker SymbolMDXG
CompanyMiMedx Group Inc
CEOCapper (Joseph H)
Websitehttps://mimedx.com/
KeyAI